After GSK and Novartis handoffs, Laekna's drug fails ovarian cancer trial

After GSK and Novartis handoffs, Laekna's drug fails ovarian cancer trial

Submitted by admin on January 29, 2024 - 10:27pm
Source: 
Fierce Biotech
News Tags: 
Laekna
afuresertib
clinical trials
ovarian cancer
GSK
Novartis
Headline: 
After GSK and Novartis handoffs, Laekna's drug fails ovarian cancer trial
snippet: 

Shanghai-based biotech Laekna's oral cancer drug afuresertib has failed to significantly improve progression-free survival for ovarian cancer patients in a phase 2 trial.

Do Not Allow Advertisers to Use My Personal information